Efficacy of GDP regimen on relapsed and refractory intermediate and high grade non-Hodgkin lymphoma

Objective Treatment of relapsed and refractory non-Hodgkin lymphoma(NHL)remains difficult.This study investigated the efficacy of the GDP(gemcitabine,dexamethasone,and cisplatin)regimen on relapsed and refractory NHL and observed the corresponding adverse events.Methods Clinical data of 32 patients with relapsed and refractory NHL(20 relapsed NHL and 12 refractory NHL)treated with GDP regimen were analyzed.Results All the 32 patients were assessable.The response rate(RR)for the whole group was 59.4 % with complete remission(CR)rate of 21.8 %.Among the 23 patients with B-cell NHL and the 9 patients with T-cell NHL,the response rates were 60.8 % and 55.5 %,respectively.The 1-year overall survival rate was 43.8 %.Major toxicity was myelosuppression with 31.1% and 18.6 % incidence of grade Ⅲ-Ⅳ thrombecytopenia and neutropenia respectively.Nausea and vomiting toxicities were mild.These adverse effects could be treated and there was no treatment-treated death.Conclusion GDP regimen is effective and well tolerated in patients with relapsed and refractory NHL.Further clinical study is needed. Key words: Lymphoma,non-Hodgkin; Drug therapy,combination; Treatment outcome